- Home
- NUW vs CADL Comparison
NUW vs CADL Comparison
Compare NUW & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- CADL
- Stock Information
- Founded
- NUW 2008
- CADL 1999
- Country
- NUW United States
- CADL United States
- Employees
- NUW N/A
- CADL N/A
- Industry
- NUW Investment Managers
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- NUW Finance
- CADL Health Care
- Exchange
- NUW Nasdaq
- CADL Nasdaq
- Market Cap
- NUW 245.0M
- CADL 234.8M
- IPO Year
- NUW N/A
- CADL 2021
- Fundamental
- Price
- NUW $13.58
- CADL $4.81
- Analyst Decision
- NUW
- CADL Strong Buy
- Analyst Count
- NUW 0
- CADL 4
- Target Price
- NUW N/A
- CADL $21.00
- AVG Volume (30 Days)
- NUW 45.3K
- CADL 900.5K
- Earning Date
- NUW 01-01-0001
- CADL 08-12-2025
- Dividend Yield
- NUW 3.66%
- CADL N/A
- EPS Growth
- NUW N/A
- CADL N/A
- EPS
- NUW N/A
- CADL N/A
- Revenue
- NUW N/A
- CADL N/A
- Revenue This Year
- NUW N/A
- CADL N/A
- Revenue Next Year
- NUW N/A
- CADL N/A
- P/E Ratio
- NUW N/A
- CADL N/A
- Revenue Growth
- NUW N/A
- CADL N/A
- 52 Week Low
- NUW $12.45
- CADL $3.79
- 52 Week High
- NUW $14.44
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- NUW 47.87
- CADL 39.51
- Support Level
- NUW $13.55
- CADL $4.84
- Resistance Level
- NUW $13.69
- CADL $6.20
- Average True Range (ATR)
- NUW 0.07
- CADL 0.36
- MACD
- NUW 0.00
- CADL -0.10
- Stochastic Oscillator
- NUW 38.89
- CADL 5.09
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.